<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39399749</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>15</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2667-646X</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Infectious diseases &amp; clinical microbiology</Title><ISOAbbreviation>Infect Dis Clin Microbiol</ISOAbbreviation></Journal><ArticleTitle>The Efficacy of Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients and the Impact of the COVID-19 Pandemic: Multicenter Real-Life Data.</ArticleTitle><Pagination><StartPage>216</StartPage><EndPage>224</EndPage><MedlinePgn>216-224</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.36519/idcm.2024.344</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">This study aimed to demonstrate the real-life efficacy and safety of glecaprevir /pibrentasvir in the treatment of chronic hepatitis C, as well as to identify the problems caused by the COVID-19 pandemic in the follow-up and treatment of patients.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="UNASSIGNED">The study was conducted retrospectively with the participation of researchers from universities or training and research hospitals. It included patients with chronic hepatitis C who were over 18 years of age, treatment-naïve or treatment-experienced, had detectable HCV RNA and were receiving glecaprevir/pibrentasvir treatment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Only 188 of the 385 patients who participated in the study came to the follow-up visit 12 weeks after treatment, and all of them had a sustained virological response. It was thought that a significant portion of the 177 patients who did not come to the follow-up visit at 12 weeks after treatment refrained from coming to the hospital due to the COVID-19 pandemic. None of the patients who attended the follow-up visits required treatment discontinuation due to adverse events.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Glecaprevir/pibrentasvir is a highly effective and relatively safe drug in the treatment of chronic hepatitis C. The COVID-19 pandemic has negatively affected the follow-up and treatment processes of patients. New measures are needed for the follow-up and treatment of patients with chronic hepatitis C during pandemics.</AbstractText><CopyrightInformation>Copyright © 2024 Infectious Diseases and Clinical Microbiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gürbüz</LastName><ForeName>Yunus</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-8772-0769</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases and Clinical Microbiology, Etlik City Hospital, Ministry of Health, Ankara, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kocagül-Çelikbaş</LastName><ForeName>Aysel</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7448-5210</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases and Clinical Microbiology, Hitit University Erol Olçok Training and Research Hospital, Çorum, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Öztoprak</LastName><ForeName>Nefise</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-6382-2229</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases and Clinical Microbiology, Antalya Training and Research Hospital, Antalya, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aygen</LastName><ForeName>Bilgehan</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-7598-6578</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases and Clinical Microbiology, Erciyes University School of Medicine, Kayseri, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Batırel</LastName><ForeName>Ayşe</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-6005-636X</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases and Clinical Microbiology, Kartal Dr. Lütfi Kırdar Municipal Hospital, İstanbul, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Habiloğlu</LastName><ForeName>Arif Doğan</ForeName><Initials>AD</Initials><Identifier Source="ORCID">0000-0001-8122-8768</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases and Clinical Microbiology, Etlik City Hospital, Ministry of Health, Ankara, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aktuğ-Demir</LastName><ForeName>Nazlım</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-4703-0827</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases and Clinical Microbiology, Selçuk University School of Medicine, Konya, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Çeken</LastName><ForeName>Sabahat</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-3679-0978</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases and Clinical Microbiology, Dr. Abdurrahman Yurtaslan University of Health Sciences, Ankara Oncology Training and Research Hospital, Ankara, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demirtürk</LastName><ForeName>Neşe</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-6186-2494</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases and Clinical Microbiology, Afyonkarahisar Health Sciences University School of Medicine, Afyonkarahisar, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ceylan</LastName><ForeName>Mehmet Reşat</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0001-8063-4836</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases and Clinical Microbiology, Harran University School of Medicine, Şanlıurfa, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Üçer</LastName><ForeName>Şengül</ForeName><Initials>Ş</Initials><Identifier Source="ORCID">0000-0002-1764-3198</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases and Clinical Microbiology, Hitit University Erol Olçok Training and Research Hospital, Çorum, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karakeçili</LastName><ForeName>Faruk</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-7368-7187</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases and Clinical Microbiology, Erzincan Binali Yıldırım University School of Medicine, Erzincan, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alkan</LastName><ForeName>Sevil</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-1944-2477</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases and Clinical Microbiology, Çanakkale 18 Mart University School of Medicine, Çanakkale, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>İnce</LastName><ForeName>Nevin</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-0129-4536</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases and Clinical Microbiology, Düzce University School of Medicine, Düzce, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akça</LastName><ForeName>Anıl</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5029-9838</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases and Clinical Microbiology, Çanakkale 18 Mart University School of Medicine, Çanakkale, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Günay</LastName><ForeName>Veli</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0001-9151-0636</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases and Clinical Microbiology, Antalya Training and Research Hospital, Antalya, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mustanoğlu-Özatağ</LastName><ForeName>Duru</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-0005-192X</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases and Clinical Microbiology, Kütahya Health Sciences University, Evliya Çelebi Training and Research Hospital, Kütahya, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Çınar</LastName><ForeName>Güle</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-7635-8848</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases and Clinical Microbiology, Ankara University School of Medicine, Ankara, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kınıklı</LastName><ForeName>Sami</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-9661-7851</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases and Clinical Microbiology, Ankara Training and Research Hospital, Ankara, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yıldız</LastName><ForeName>Orhan</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0001-6019-0430</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases and Clinical Microbiology, Erciyes University School of Medicine, Kayseri, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Şarlak-Konya</LastName><ForeName>Petek</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-5055-1220</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases and Clinical Microbiology, Afyonkarahisar Health Sciences University School of Medicine, Afyonkarahisar, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sümer</LastName><ForeName>Şua</ForeName><Initials>Ş</Initials><Identifier Source="ORCID">0000-0003-3508-7516</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases and Clinical Microbiology, Selçuk University School of Medicine, Konya, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yekenkurul</LastName><ForeName>Dilek</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-4456-7485</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases and Clinical Microbiology, Düzce University School of Medicine, Düzce, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Çelik</LastName><ForeName>Mehmet</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0583-929X</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases and Clinical Microbiology, Harran University School of Medicine, Şanlıurfa, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Binay</LastName><ForeName>Umut Devrim</ForeName><Initials>UD</Initials><Identifier Source="ORCID">0000-0003-3841-9109</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases and Clinical Microbiology, Erzincan Binali Yıldırım University School of Medicine, Erzincan, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aşık-Otman</LastName><ForeName>Zahide</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0002-1729-2922</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases and Clinical Microbiology, Antalya Training and Research Hospital, Antalya, Türkiye.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Turkey</Country><MedlineTA>Infect Dis Clin Microbiol</MedlineTA><NlmUniqueID>9918680988406676</NlmUniqueID><ISSNLinking>2667-646X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">chronic hepatitis C</Keyword><Keyword MajorTopicYN="N">glecaprevir</Keyword><Keyword MajorTopicYN="N">multicenter study</Keyword><Keyword MajorTopicYN="N">pibrentasvir</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>7</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39399749</ArticleId><ArticleId IdType="pmc">PMC11465448</ArticleId><ArticleId IdType="doi">10.36519/idcm.2024.344</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Seeff LB. The history of the “natural history” of hepatitis C (1968-2009) Liver Int. 2009;(29 Suppl 1(0 1)):89–99. doi: 10.1111/j.1478-3231.2008.01927.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1478-3231.2008.01927.x</ArticleId><ArticleId IdType="pmc">PMC4373556</ArticleId><ArticleId IdType="pubmed">19207971</ArticleId></ArticleIdList></Reference><Reference><Citation>Global hepatitis report, 2017. Geneva: World Health Organization (WHO)  [March 23, 2024]. 
https://iris.who.int/bitstream/handle/10665/255016/9789241565455-eng.pdf </Citation></Reference><Reference><Citation>Hepatitis C: Key facts. Geneva: World Health Organization (WHO)  [November 15, 2023].  [April 9, 2024]. 
https://www.who.int/news-room/fact-sheets/detail/hepatitis-c </Citation></Reference><Reference><Citation>Tosun S. [The changing viral hepatitis epidemiology in our country] ANKEM Derg. 2013;27(2):128–134. Turkish.</Citation></Reference><Reference><Citation>Tozun N, Ozdogan O, Cakaloglu Y, Idilman R, Karasu Z, Akarca U, et al. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect. 2015;21(11):1020–1026. doi: 10.1016/j.cmi.2015.06.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2015.06.028</ArticleId><ArticleId IdType="pubmed">26163105</ArticleId></ArticleIdList></Reference><Reference><Citation>Gürbüz Y, Tülek NE, Tütüncü EE, Koruk ST, Aygen B, Demirtürk N, et al. Evaluation of dual therapy in real life setting in treatment-naïve Turkish patients with HCV infection: a multicenter, retrospective study. Balkan Med J. 2016;33(1):18–26. doi: 10.5152/balkanmedj.2015.15859.</Citation><ArticleIdList><ArticleId IdType="doi">10.5152/balkanmedj.2015.15859</ArticleId><ArticleId IdType="pmc">PMC4767305</ArticleId><ArticleId IdType="pubmed">26966614</ArticleId></ArticleIdList></Reference><Reference><Citation>Çetin Duran A, Kaya Çetinkaya Ö, Sayıner AA, Şeydaoğlu G, Özkarataş E, Abacıoğlu H. Changes on hepatitis C virus genotype distribution in Western Turkey: Evaluation of twelve-year data. Turk J Gastroenterol. 2020;31(2):128–135. doi: 10.5152/tjg.2020.18798.</Citation><ArticleIdList><ArticleId IdType="doi">10.5152/tjg.2020.18798</ArticleId><ArticleId IdType="pmc">PMC7062126</ArticleId><ArticleId IdType="pubmed">32141821</ArticleId></ArticleIdList></Reference><Reference><Citation>Flori N, Funakoshi N, Duny Y, Valats JC, Bismuth M, Christophorou D, et al. Pegylated interferon-α2a and ribavirin versus pegylated interferon-α2b and ribavirin in chronic hepatitis C: a meta-analysis. Drugs. 2013;73(3):263–277. doi: 10.1007/s40265-013-0027-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-013-0027-1</ArticleId><ArticleId IdType="pubmed">23436591</ArticleId></ArticleIdList></Reference><Reference><Citation>Swiss Association for the Study of the Liver. Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir. Swiss Med Wkly. 2012;142:w13516. doi: 10.4414/smw.2012.13516.</Citation><ArticleIdList><ArticleId IdType="doi">10.4414/smw.2012.13516</ArticleId><ArticleId IdType="pubmed">22367957</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumert TF, Berg T, Lim JK, Nelson DR. Status of direct-acting antiviral therapy for hepatitis C virus infection and remaining challenges. Gastroenterology. 2019;156(2):431–445. doi: 10.1053/j.gastro.2018.10.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2018.10.024</ArticleId><ArticleId IdType="pmc">PMC6446912</ArticleId><ArticleId IdType="pubmed">30342035</ArticleId></ArticleIdList></Reference><Reference><Citation>Glecaprevir/pibrentasvir for hepatitis C. Aust Prescr. 2018;41(5):169–170. doi: 10.18773/austprescr.2018.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.18773/austprescr.2018.050</ArticleId><ArticleId IdType="pmc">PMC6202291</ArticleId><ArticleId IdType="pubmed">30410216</ArticleId></ArticleIdList></Reference><Reference><Citation>Flamm S, Mutimer D, Asatryan A, Wang S, Rockstroh J, Horsmans Y, et al. Glecaprevir/pibrentasvir in patients with chronic HCV genotype 3 infection: an integrated phase 2/3 analysis. J Viral Hepat. 2019;26(3):337–349. doi: 10.1111/jvh.13038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jvh.13038</ArticleId><ArticleId IdType="pmc">PMC7379735</ArticleId><ArticleId IdType="pubmed">30421537</ArticleId></ArticleIdList></Reference><Reference><Citation>Puoti M, Foster GR, Wang S, Mutimer D, Gane E, Moreno C, et al. High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis. J Hepatol. 2018;69(2):293–300. doi: 10.1016/j.jhep.2018.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2018.03.007</ArticleId><ArticleId IdType="pubmed">29551706</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg T, Naumann U, Stoehr A, Sick C, John C, Teuber G, et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry. Aliment Pharmacol Ther. 2019;49(8):1052–1059. doi: 10.1111/apt.15222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15222</ArticleId><ArticleId IdType="pubmed">30874328</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Ambrosio R, Pasulo L, Puoti M, Vinci M, Schiavini M, Lazzaroni S, et al. NAVIGATORE-Lombardia Study Group. Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C. J Hepatol. 2019;70(3):379–387. doi: 10.1016/j.jhep.2018.11.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2018.11.011</ArticleId><ArticleId IdType="pubmed">30472321</ArticleId></ArticleIdList></Reference><Reference><Citation>Laury J, Hiebert L, Ward JW. Impact of COVID-19 response on hepatitis prevention care and treatment: results from global survey of providers and program managers. Clin Liver Dis (Hoboken) 2021;17(1):41–46. doi: 10.1002/cld.1088. Erratum in: Clin Liver Dis (Hoboken). 2021;17(5):382.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cld.1088</ArticleId><ArticleId IdType="pmc">PMC7849293</ArticleId><ArticleId IdType="pubmed">33552486</ArticleId></ArticleIdList></Reference><Reference><Citation>Loaeza-del-Castillo A, Paz-Pineda F, Oviedo-Cárdenas E, Sánchez-Avila F, Vargas-Vorácková F. AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. Ann Hepatol. 2008;7(4):350–357.</Citation><ArticleIdList><ArticleId IdType="pubmed">19034235</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011;53(3):726–736. doi: 10.1002/hep.24105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.24105</ArticleId><ArticleId IdType="pubmed">21319189</ArticleId></ArticleIdList></Reference><Reference><Citation>Global progress report on HIV, viral hepatitis and sexually transmitted
infections, 2021. Geneva: World Health Organization (WHO)  [November 16, 2022]. 
https://iris.who.int/bitstream/handle/10665/341412/9789240027077-eng.pdf?sequence=1 </Citation></Reference><Reference><Citation>Gamkrelidze A, Handanagic S, Shadaker S, Turdziladze A, Tsereteli M, Getia V, et al. The impact of COVID-19 pandemic on the 2020 hepatitis C cascade of care in the Republic of Georgia. Public Health. 2022;205:182–186. doi: 10.1016/j.puhe.2022.01.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.puhe.2022.01.040</ArticleId><ArticleId IdType="pmc">PMC9004234</ArticleId><ArticleId IdType="pubmed">35305459</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman HW, Bull-Otterson L, Meyer WA 3rd, Huang X, Doshani M, Thompson WW, et al. Decreases in hepatitis C testing and treatment during the COVID-19 pandemic. Am J Prev Med. 2021;61(3):369–376. doi: 10.1016/j.amepre.2021.03.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amepre.2021.03.011</ArticleId><ArticleId IdType="pmc">PMC8107198</ArticleId><ArticleId IdType="pubmed">34088556</ArticleId></ArticleIdList></Reference><Reference><Citation>İskender G. [Effect of the COVID-19 pandemic on chronic viral hepatitis services] Kesit Akademi Dergisi. 2020;6(25):685–693. doi: 10.29228/kesit.47391. Turkish.</Citation><ArticleIdList><ArticleId IdType="doi">10.29228/kesit.47391</ArticleId></ArticleIdList></Reference><Reference><Citation>Fix OK, Hameed B, Fontana RJ, Kwok RM, McGuire BM, Mulligan DC, et al. Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD Expert Panel Consensus Statement. Hepatology. 2020;72(1):287–304. doi: 10.1002/hep.31281.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.31281</ArticleId><ArticleId IdType="pmc">PMC7262242</ArticleId><ArticleId IdType="pubmed">32298473</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy KR. SARS-CoV-2 and the liver: considerations in hepatitis B and hepatitis C infections. Clin Liver Dis (Hoboken) 2020;15(5):191–194. doi: 10.1002/cld.970.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cld.970</ArticleId><ArticleId IdType="pmc">PMC7242007</ArticleId><ArticleId IdType="pubmed">32489654</ArticleId></ArticleIdList></Reference><Reference><Citation>Müllhaupt B, Semela D, Ruckstuhl L, Magenta L, Clerc O, Torgler R, et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir therapy in patients with chronic hepatitis C virus infection in Switzerland. Swiss Med Wkly. 2021;151:w20399. doi: 10.4414/smw.2021.20399.</Citation><ArticleIdList><ArticleId IdType="doi">10.4414/smw.2021.20399</ArticleId><ArticleId IdType="pubmed">33516161</ArticleId></ArticleIdList></Reference><Reference><Citation>Nozaki A, Atsukawa M, Kondo C, Toyoda H, Chuma M, Nakamuta M, et al. KTK49 Liver Study Group. The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study. Hepatol Int. 2020;14(2):225–238. doi: 10.1007/s12072-020-10019-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12072-020-10019-z</ArticleId><ArticleId IdType="pubmed">32128704</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilgehan A, Gürbüz Y, Çetinkaya RA, Cinar G, Kayabas U, Ormen B, et al. [Management of chronic hepatitis C virus infection: A consensus report of the Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases-2023 Update] Klimik Derg. 2023;36(1):43–75. doi: 10.36519/kd.2023.4672. Turkish.</Citation><ArticleIdList><ArticleId IdType="doi">10.36519/kd.2023.4672</ArticleId></ArticleIdList></Reference><Reference><Citation>Demirtürk N, Aygen B, Çelik İ, Mıstık R, Akhan S, Barut Ş, et al. Real-world data from Turkey: Is sofosbuvir/ledipasvir with or without ribavirin treatment for chronic hepatitis C really effective? Turk J Gastroenterol. 2021;32(2):155–163. doi: 10.5152/tjg.2020.19569.</Citation><ArticleIdList><ArticleId IdType="doi">10.5152/tjg.2020.19569</ArticleId><ArticleId IdType="pmc">PMC8975436</ArticleId><ArticleId IdType="pubmed">33960939</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper MP, Foley H, Damico D, Wright M, Rhudy C, Schadler A, et al. Impact of the COVID-19 pandemic on hepatitis C outcomes at a health-system specialty pharmacy. J Manag Care Spec Pharm. 2022;28(6):667–672. doi: 10.18553/jmcp.2022.28.6.667.</Citation><ArticleIdList><ArticleId IdType="doi">10.18553/jmcp.2022.28.6.667</ArticleId><ArticleId IdType="pmc">PMC10372976</ArticleId><ArticleId IdType="pubmed">35621721</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>